We are analyzing https://link.springer.com/article/10.1007/s00262-013-1396-8.

Title:
Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer | Cancer Immunology, Immunotherapy
Description:
Myeloid-derived suppressor cells (MDSC) are one of the major factors limiting the efficacy of immune therapy. In a clinical trial of patients with extensive stage small cell lung cancer (SCLC), we tested the possibility that targeting MDSC can improve the induction of immune responses by a cancer vaccine. Forty-one patients with extensive stage SCLC were randomized into three arms: arm A—control, arm B—vaccination with dendritic cells transduced with wild-type p53, and arm C—vaccination in combination with MDSC targeted therapy with all-trans-retinoic acid (ATRA). Interim results of the ongoing clinical trial are presented. Pre-treatment levels of MDSC populations in patients from all three arms were similar. Vaccine alone did not affect the proportion of MDSC, whereas in patients treated with ATRA, the MDSC decreased more than twofold (p = 0.02). Before the start of treatment, no patients had detectable p53-specific responses in IFN-γ ELISPOT. Sequential measurements did not show positive p53 responses in any of the 14 patients from arm A. After immunization, only 3 out of 15 patients (20 %) from arm B developed a p53-specific response (p = 0.22). In contrast, in arm C, 5 out of 12 patients (41.7 %) had detectable p53 responses (p = 0.012). The proportion of granzyme B-positive CD8+ T cells was increased only in patients from arm C but not in arm B. Depletion of MDSC substantially improved the immune response to vaccination, suggesting that this approach can be used to enhance the effect of immune interventions in cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 8,049,684 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cancer, article, google, scholar, pubmed, cas, cells, patients, suppressor, myeloidderived, cell, gabrilovich, immune, immunol, vaccine, acid, clin, res, response, lung, immunotherapy, stage, clinical, arm, myeloid, antonia, mdsc, access, lee, small, trial, alltransretinoic, chemotherapy, nat, rev, oncol, privacy, cookies, content, extensive, chiappori, therapy, dendritic, combination, treatment, phase, retinoic, information, publish, search,

Topics {✒️}

dung-tsa chen & dmitry gabrilovich interferon-gamma-producing t-cells small-cell lung cancer myeloid-derived suppressor cells month download article/chapter immature gr-1 + myeloid cells functional antigen-presenting cells trans-retinoic acid treatment myeloid cell-mediated immunosuppression granzyme b-positive cd8+ inhibitory b7-family molecules il-1alpha vaccine depends myeloid suppressor cells immature myeloid cells wild-type p53 single-dose cyclophosphamide associates trans-retinoic acid detectable p53-specific responses diaz-montero cm full article pdf article cancer immunology extensive stage sclc cell therapy core clinical cancer stage related subjects p53 cancer vaccine dendritic cells transduced colony-stimulating factors privacy choices/manage cookies p53-specific response cancer vaccine ima901 lung cancer 40 affecting th17 cells detectable p53 responses tumour microenvironment metastatic tumor burden fusion protein vaccine multipeptide immune response improves immune response authors cristina iclozan myeloid cells tumor-induced tolerance interleukin-12-secreting dendritic cell response il-1ri availability article iclozan check access instant access ongoing clinical trial pdf+html kotsakis

Questions {❓}

Wieand HS (2005) Randomized phase II trials: what does randomization gain?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
         description:Myeloid-derived suppressor cells (MDSC) are one of the major factors limiting the efficacy of immune therapy. In a clinical trial of patients with extensive stage small cell lung cancer (SCLC), we tested the possibility that targeting MDSC can improve the induction of immune responses by a cancer vaccine. Forty-one patients with extensive stage SCLC were randomized into three arms: arm A—control, arm B—vaccination with dendritic cells transduced with wild-type p53, and arm C—vaccination in combination with MDSC targeted therapy with all-trans-retinoic acid (ATRA). Interim results of the ongoing clinical trial are presented. Pre-treatment levels of MDSC populations in patients from all three arms were similar. Vaccine alone did not affect the proportion of MDSC, whereas in patients treated with ATRA, the MDSC decreased more than twofold (p = 0.02). Before the start of treatment, no patients had detectable p53-specific responses in IFN-γ ELISPOT. Sequential measurements did not show positive p53 responses in any of the 14 patients from arm A. After immunization, only 3 out of 15 patients (20 %) from arm B developed a p53-specific response (p = 0.22). In contrast, in arm C, 5 out of 12 patients (41.7 %) had detectable p53 responses (p = 0.012). The proportion of granzyme B-positive CD8+ T cells was increased only in patients from arm C but not in arm B. Depletion of MDSC substantially improved the immune response to vaccination, suggesting that this approach can be used to enhance the effect of immune interventions in cancer.
         datePublished:2013-04-16T00:00:00Z
         dateModified:2013-04-16T00:00:00Z
         pageStart:909
         pageEnd:918
         sameAs:https://doi.org/10.1007/s00262-013-1396-8
         keywords:
            Cancer vaccine
            Myeloid-derived suppressor cells
            Small cell lung cancer
            All-trans-retinoic acid
            Dendritic cells
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1396-8/MediaObjects/262_2013_1396_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1396-8/MediaObjects/262_2013_1396_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1396-8/MediaObjects/262_2013_1396_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1396-8/MediaObjects/262_2013_1396_Fig4_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:62
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Cristina Iclozan
               affiliation:
                     name:H. Lee Moffitt Cancer Center
                     address:
                        name:H. Lee Moffitt Cancer Center, Tampa, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Scott Antonia
               affiliation:
                     name:H. Lee Moffitt Cancer Center
                     address:
                        name:H. Lee Moffitt Cancer Center, Tampa, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alberto Chiappori
               affiliation:
                     name:H. Lee Moffitt Cancer Center
                     address:
                        name:H. Lee Moffitt Cancer Center, Tampa, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dung-Tsa Chen
               affiliation:
                     name:H. Lee Moffitt Cancer Center
                     address:
                        name:H. Lee Moffitt Cancer Center, Tampa, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dmitry Gabrilovich
               affiliation:
                     name:H. Lee Moffitt Cancer Center
                     address:
                        name:H. Lee Moffitt Cancer Center, Tampa, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
      description:Myeloid-derived suppressor cells (MDSC) are one of the major factors limiting the efficacy of immune therapy. In a clinical trial of patients with extensive stage small cell lung cancer (SCLC), we tested the possibility that targeting MDSC can improve the induction of immune responses by a cancer vaccine. Forty-one patients with extensive stage SCLC were randomized into three arms: arm A—control, arm B—vaccination with dendritic cells transduced with wild-type p53, and arm C—vaccination in combination with MDSC targeted therapy with all-trans-retinoic acid (ATRA). Interim results of the ongoing clinical trial are presented. Pre-treatment levels of MDSC populations in patients from all three arms were similar. Vaccine alone did not affect the proportion of MDSC, whereas in patients treated with ATRA, the MDSC decreased more than twofold (p = 0.02). Before the start of treatment, no patients had detectable p53-specific responses in IFN-γ ELISPOT. Sequential measurements did not show positive p53 responses in any of the 14 patients from arm A. After immunization, only 3 out of 15 patients (20 %) from arm B developed a p53-specific response (p = 0.22). In contrast, in arm C, 5 out of 12 patients (41.7 %) had detectable p53 responses (p = 0.012). The proportion of granzyme B-positive CD8+ T cells was increased only in patients from arm C but not in arm B. Depletion of MDSC substantially improved the immune response to vaccination, suggesting that this approach can be used to enhance the effect of immune interventions in cancer.
      datePublished:2013-04-16T00:00:00Z
      dateModified:2013-04-16T00:00:00Z
      pageStart:909
      pageEnd:918
      sameAs:https://doi.org/10.1007/s00262-013-1396-8
      keywords:
         Cancer vaccine
         Myeloid-derived suppressor cells
         Small cell lung cancer
         All-trans-retinoic acid
         Dendritic cells
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1396-8/MediaObjects/262_2013_1396_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1396-8/MediaObjects/262_2013_1396_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1396-8/MediaObjects/262_2013_1396_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1396-8/MediaObjects/262_2013_1396_Fig4_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:62
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Cristina Iclozan
            affiliation:
                  name:H. Lee Moffitt Cancer Center
                  address:
                     name:H. Lee Moffitt Cancer Center, Tampa, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Scott Antonia
            affiliation:
                  name:H. Lee Moffitt Cancer Center
                  address:
                     name:H. Lee Moffitt Cancer Center, Tampa, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alberto Chiappori
            affiliation:
                  name:H. Lee Moffitt Cancer Center
                  address:
                     name:H. Lee Moffitt Cancer Center, Tampa, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dung-Tsa Chen
            affiliation:
                  name:H. Lee Moffitt Cancer Center
                  address:
                     name:H. Lee Moffitt Cancer Center, Tampa, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dmitry Gabrilovich
            affiliation:
                  name:H. Lee Moffitt Cancer Center
                  address:
                     name:H. Lee Moffitt Cancer Center, Tampa, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:62
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:H. Lee Moffitt Cancer Center
      address:
         name:H. Lee Moffitt Cancer Center, Tampa, USA
         type:PostalAddress
      name:H. Lee Moffitt Cancer Center
      address:
         name:H. Lee Moffitt Cancer Center, Tampa, USA
         type:PostalAddress
      name:H. Lee Moffitt Cancer Center
      address:
         name:H. Lee Moffitt Cancer Center, Tampa, USA
         type:PostalAddress
      name:H. Lee Moffitt Cancer Center
      address:
         name:H. Lee Moffitt Cancer Center, Tampa, USA
         type:PostalAddress
      name:H. Lee Moffitt Cancer Center
      address:
         name:H. Lee Moffitt Cancer Center, Tampa, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Cristina Iclozan
      affiliation:
            name:H. Lee Moffitt Cancer Center
            address:
               name:H. Lee Moffitt Cancer Center, Tampa, USA
               type:PostalAddress
            type:Organization
      name:Scott Antonia
      affiliation:
            name:H. Lee Moffitt Cancer Center
            address:
               name:H. Lee Moffitt Cancer Center, Tampa, USA
               type:PostalAddress
            type:Organization
      name:Alberto Chiappori
      affiliation:
            name:H. Lee Moffitt Cancer Center
            address:
               name:H. Lee Moffitt Cancer Center, Tampa, USA
               type:PostalAddress
            type:Organization
      name:Dung-Tsa Chen
      affiliation:
            name:H. Lee Moffitt Cancer Center
            address:
               name:H. Lee Moffitt Cancer Center, Tampa, USA
               type:PostalAddress
            type:Organization
      name:Dmitry Gabrilovich
      affiliation:
            name:H. Lee Moffitt Cancer Center
            address:
               name:H. Lee Moffitt Cancer Center, Tampa, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:H. Lee Moffitt Cancer Center, Tampa, USA
      name:H. Lee Moffitt Cancer Center, Tampa, USA
      name:H. Lee Moffitt Cancer Center, Tampa, USA
      name:H. Lee Moffitt Cancer Center, Tampa, USA
      name:H. Lee Moffitt Cancer Center, Tampa, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(160)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.9s.

LINK . SPRINGER . COM {}